Ixico to adapt Healthcare Platform under Collaborative Project

IXICO plc, which has entered into a strategic collaboration with a leading pharmaceutical company and independent expert clinical centres in the management of multiple sclerosis, is to develop an adapted version of Assessa®, its CE marked digital healthcare platform, to assist in the monitoring and management of people receiving approved pharmaceutical treatments for multiple sclerosis (‘MS’) in the EU and Canada;  it is anticipated that the digital platform will be deployed in a clinical setting in 2016.

The adapted platform will specifically facilitate remote MRI assessment in the monitoring of patients who might be at a higher risk of developing progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. IXICO will be funded to develop, validate and pilot the adapted version of the Assessa® platform in the context of PML suspicion with the intention to roll out and operate the platform internationally thereafter.

Professor Derek Hill, Chief Executive of IXICO commented: “This is an important strategic opportunity for IXICO in that it represents the first deployment of an adapted version of our Assessa® digital platform to support the safety monitoring of approved pharmaceutical treatments in the important area of multiple sclerosis.  We expect this collaboration to make a material contribution to our revenues in the next 12-18 months thereby underpinning the board’s confidence in meeting current market expectations.”